首页> 外国专利> Derivatives of piperidine antagonists of CXCR3 Receptors, Preparation Method, Pharmaceutical compositions containing them and uses for treating Diseases mediated by CXCR3 receptor activation.

Derivatives of piperidine antagonists of CXCR3 Receptors, Preparation Method, Pharmaceutical compositions containing them and uses for treating Diseases mediated by CXCR3 receptor activation.

机译:CXCR3受体的哌啶拮抗剂的衍生物,制备方法,含有它们的药物组合物以及用于治疗由CXCR3受体激活介导的疾病的用途。

摘要

Item 1: a formula compound (1)a. N-oxidizes the compound, a pharmaceutically acceptable salt of the compound, a stereoisomerized isomer or solution of the compound, wherein X represents n or CH; y and Z independently represent C (= O) or CH2, provided that at least one of Y and Z represents C (= O);R1 represents CH (R4) -aryl or CH (R4) -heteroaryl; R2 represents aryl2 or heteroaryl; R3 represents H, C1-4 alkylcarbonyl, C1-6 alkyl optionally substituted with C1-6 alkyloxy, C1-6 alkylthio, C1-6 alkyloxycarbonyl or aryl1; R4 represents H or C1-4 alkyl; R5 and R6 independently represent H or C1-6 alkyl optionally substituted with hydroxyl; or R5 and R6 together with the N to which they are attached form a monocyclic heterocycle selected from piperidinyl, piperazinyl, morpholinyl, or thiomorpholinyl, where each of said rings is optionally substituted with C1-4 alkyl; R7 represents H or C1-4 alkyl; aryl represents unsubstituted naphthyl; or phenyl or naphthyl,wherein each of said phenyl or naphthyl is substituted with at least one substituent, where each substituent is independently selected from halo, hydroxyl, C1-6 alkyloxy, C1-6 alkyloxycarbonyl, C1-6 alkylcarbonyloxy, C1-6 alkylthio , polyhalo-C1-6 alkyl, polyhalo-C1-6 alkyloxy, cyano, nitro, carboxyl, HO-SO2-,A c1-4-so2R6R5N-C (3DO) -1. Amino, mono-o di (C1-4 tar) amino, C1-4 C1-4 asphalt, arilo1, arilo1-c1-4 asphalt, arilo1oxi, O arilo1c (= O) -;aryl1 represents phenyl or phenyl substituted with 1; 2 or 3 substituents, where each substituent is independently selected from halo, hydroxyl, C1-6 alkyl, C1-6 alkyloxy, C1-6 alkyloxycarbonyl, C1-6 alkylcarbonyloxy, C1-6 alkylthio, polyhalo-C1-6 alkyl, polyhalo-C 1-6 alkyloxy, cyano, nitro, carboxyl, aminocarbonyl, mono- or di (C 1-4 alkyl) aminocarbonyl, amino, or mono- or di (C 1-4 alkyl) amino; aryl2 represents phenyl or naphthyl, where each of said rings is optionally substituted with at least one substituent, where each substituent is independently selected from halo, hydroxyl, C1-6 alkyl, C1-6 alkyloxy, C1-6 alkyloxycarbonyl,C1-6 alkylcarbonyloxy, C1-6 alkylthio, C1-6 polyhalo-alkyl, C1-6 polyhalo-alkyloxy, cyano, nitro, carboxyl, HO-SO2-,A c1-4-so2R6R5N-C (3DO) -1. Amino, mono-o di (C1-4 tar) amino, C1-4 C1-4 asphalt, arilo1, arilo1-c1-4 asphalt, arilo1oxi, O arilo1c (= O) -;heteroaryl represents a selected monocyclic heterocycle pyrrolinyl, imidazolinyl, pyrazolinyl, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, piperidinyl, piperazinyl, morpholinyl thiomorpholinyl; or bicyclic heterocycle selected from indolyl, indolizinyl, isoindolyl, indolinyl, benzofuranyl, benzothienyl, indazolyl, benzimidazolyl, benzthiazolyl, purinyl, quinolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthyridinyl, pteridinyl, benzoxadiazolyl, benzoxazolyl,benzthiazolyl, wherein each of said monocyclic or bicyclic heterocycles is optionally substituted with at least one substituent, where each substituent is independently selected from halo, hydroxyl, C1-6 alkyl, C1-6 alkyloxy, C1-6 alkyloxycarbonyl, alkylcarbonyloxy C1-6, C1-6 alkylthio, C1-6 polyhalo-alkyl, C1-6 polyhalo-alkyloxy, cyano, nitro, carboxyl, HO-SO2-,A c1-4-so2R6R5N-C (3DO) -1. Amino, mono-o di (C1-4 tar) amine, O lcarbonilamino C1-4, provided that y and Z independently represent C (= O),X represents ch, R3 represents hydrogen, R4 represents hydrogen, R2 represents unreplaced pyridine, or substituted pyridine, or pyridine substituted with halogen or C1-4 tar or one or two C1-4 tar, so in the definition of R1, arilo is not a phenyl substituted with halogen or one or two C1-4 tar; and the condition is that it represents y and Z Independent, independentX stands for CH, R3 stands for hydrogen, R2 stands for pyridine that is not replaced, or pyridine that is replaced by halogen or C1-4 tar or one or two C1-4 tar alternatively. Therefore, in the definition of R1, non-n-octanol is not an unreplaced or unreplaced pyridine.
机译:第1项:式(1)a化合物。 N-氧化化合物,化合物的药学上可接受的盐,立体异构化的异构体或化合物的溶液,其中X代表n或CH; y和Z独立地代表C(= O)或CH 2,条件是Y和Z中的至少一个代表C(= O); R 1代表CH(R 4)-芳基或CH(R 4)-杂芳基; R2代表芳基2或杂芳基; R 3代表H,C 1-4烷基羰基,任选被C 1-6烷氧基,C 1-6烷硫基,C 1-6烷氧基羰基或芳基1取代的C 1-6烷基; R4代表H或C1-4烷基; R5和R6独立地代表任选被羟基取代的H或C1-6烷基; R5和R6与它们所连接的N一起形成选自哌啶基,哌嗪基,吗啉基或硫代吗啉基的单环杂环,其中每个所述环任选地被C1-4烷基取代; R7代表H或C1-4烷基;芳基代表未取代的萘基;或苯基或萘基,其中每个所述苯基或萘基被至少一个取代基取代,其中每个取代基独立地选自卤素,羟基,C 1-6烷氧基,C 1-6烷氧基羰基,C 1-6烷基羰氧基,C 1-6烷硫基,多卤代-C1-6烷基,多卤代-C1-6烷氧基,氰基,硝基,羧基,HO-SO2-,A c1-4-so2R6R5N-C(3DO)-1。氨基,单邻二(C1-4焦油)氨基,C1-4 C1-4沥青,arilo1,arilo1-c1-4沥青,arilo1oxi,O arilo1c(= O)-;芳基1代表苯基或被1取代的苯基; 2或3个取代基,其中每个取代基独立地选自卤素,羟基,C 1-6烷基,C 1-6烷氧基,C 1-6烷氧基羰基,C 1-6烷基羰氧基,C 1-6烷硫基,多卤代-C 1-6烷基,多卤代- C 1-6烷氧基,氰基,硝基,羧基,氨基羰基,单或二(C 1-4烷基)氨基羰基,氨基或单或二(C 1-4烷基)氨基;芳基2代表苯基或萘基,其中每个所述环任选地被至少一个取代基取代,其中每个取代基独立地选自卤素,羟基,C 1-6烷基,C 1-6烷氧基,C 1-6烷氧基羰基,C 1-6烷基羰氧基,C 1-6烷硫基,C 1-6聚卤代烷基,C 1-6聚卤代烷氧基,氰基,硝基,羧基,HO-SO 2-,C 1-4 -so 2 R 6 R 5 N-C(3DO)-1。氨基,单邻二(C1-4焦油)氨基,C1-4 C1-4沥青,arilo1,arilo1-c1-4沥青,arilo1oxi,O arilo1c(= O)-;杂芳基表示选定的单环杂环吡咯烷基,咪唑啉基,吡唑啉基,呋喃基,噻吩基,吡咯基,恶唑基,噻唑基,咪唑基,吡唑基,异恶唑基,异噻唑基,恶二唑基,三唑基,噻二唑基,吡啶基,哒嗪基,嘧啶基,吡嗪基,哌啶基,哌啶基或选自吲哚基,吲哚嗪基,异吲哚基,吲哚基,苯并呋喃基,苯并噻吩基,吲唑基,苯并咪唑基,苯并噻唑基,嘌呤基,喹嗪基,喹啉基,异喹啉基,邻苯二甲酰基,苯二甲酰基,萘二甲酰基,萘二甲酰基,萘甲酰基,萘甲酰基,萘甲酰基,萘甲酰基,萘二甲酰基,萘甲酰基,萘甲酰基,萘甲酰基,萘甲酰基,萘甲酰基,萘甲酰基,萘甲酰基,萘甲酰基,萘甲酰基,萘甲酰基,萘甲酰基,萘甲酰基,萘甲酰基,萘甲酰基,萘甲酰基,萘甲酰基,萘甲酰基,萘甲酰基,萘甲酰基,萘甲酰基,邻苯二甲酰基,二-苯二甲酰基,二苯甲酰基-苯二甲酰基每个所述单环或双环杂环任选地被至少一个取代基取代,其中每个取代基独立地选自卤素,羟基,C 1-6烷基,C 1-6烷氧基,C 1-6烷氧基羰基,烷基羰氧基C 1-6,C 1-6。烷硫基,C 1-6多卤代烷基,C 1-6多卤代烷氧基,氰基,硝基,羧基,HO-SO 2-,C 1-4 -so 2 R 6 R 5 N-C(3DO)-1。氨基,单邻二(C1-4焦油)胺,Ol碳氨氨基C1-4,条件是y和Z独立代表C(= O),X代表ch,R3代表氢,R4代表氢,R2代表未取代的吡啶,或取代的吡啶,或被卤素或C1-4焦油或一个或两个C1-4焦油取代的吡啶,因此在R1的定义中,芳基不是被卤素或一个或两个C1-4焦油取代的苯基;且条件是它代表y和Z独立,独立X代表CH,R3代表氢,R2代表未取代的吡啶或被卤素或C1-4焦油或一个或两个C1-4取代的吡啶焦油替代。因此,在R 1的定义中,非正辛醇不是未取代的或未取代的吡啶。

著录项

  • 公开/公告号AR059426A1

    专利类型

  • 公开/公告日2008-04-09

    原文格式PDF

  • 申请/专利权人 JANSSEN PHARMACEUTICA N.V.;

    申请/专利号AR2007P100557

  • 发明设计人

    申请日2007-02-09

  • 分类号C07D401/04;C07D401/14;A61K31/496;A61K31/4545;A61P29/00;A61P37/06;A61P37/08;

  • 国家 AR

  • 入库时间 2022-08-21 20:08:59

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号